WO2006119912A2 - Verwendung von histonen zu therapeutischen zwecken - Google Patents
Verwendung von histonen zu therapeutischen zwecken Download PDFInfo
- Publication number
- WO2006119912A2 WO2006119912A2 PCT/EP2006/004167 EP2006004167W WO2006119912A2 WO 2006119912 A2 WO2006119912 A2 WO 2006119912A2 EP 2006004167 W EP2006004167 W EP 2006004167W WO 2006119912 A2 WO2006119912 A2 WO 2006119912A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- histone
- thrombocytopenia
- therapeutically effective
- portion according
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Definitions
- the invention relates to the use of at least one human recombinant histone H 1 subtype and / or its therapeutically effective portion, in particular histone H1.3 for therapeutic purposes.
- CTU-S histone H1 and H2A / H2B fractions of calf thymus on hematological stem cells
- thrombocytopenia In complex clinical pictures such as acute myeloid leukemia, thrombocytopenia is frequently observed, which can be exacerbated by chemotherapeutic treatment of leukemia. Thrombocytopenia is also observed in other etiologies. Since thrombocytopenia can lead to life-threatening internal bleeding, therapies for a variety of disease symptoms, which can be the cause of thrombocytopenia, often particularly difficult.
- the object of the invention was therefore to find a therapeutically useful drug against thrombocytopenia in order to improve significantly the healing success of the basic symptom as a trigger of thrombocytopenia.
- the object could be achieved according to the invention that for the therapy of thrombocytopenia, inter alia, as a result of defective stem cell differentiation or weakened proliferation of megakaryocytes, an active ingredient on the basis of at least one human recombinant histone (especially at least one histone H 1 subtype) and / or its therapeutic effective section is used.
- the therapeutic method according to the invention for the treatment of thrombocytopenia during or after chemotherapy for the treatment of a hematological disorder, in particular the acute myeloid leukemia can be applied.
- the active ingredient according to the invention on the one hand shows a positive result in the treatment of a hematological disease such as leukemia, on the other hand, but also a positive result in the treatment of associated with hematological diseases thrombocytopenia.
- One and the same drug showed a decrease in leukemia as well as an increase in platelets.
- Therapeutic test results also on patients could be achieved with human recombinant histone H1.3, whereby the number of pathological tumor cells in an AML patient could be significantly reduced and at the same time the platelet production significantly increased, whereby the chances of recovery of the patient could be significantly improved.
- the platelets in the peripheral blood are in a number from 0 to 40. 10 9 .
- the abscissa shows a three-week treatment with inventive drug, wherein the patient before the first treatment, a greatly reduced platelet count of about 8. 10 9 was measured. There are then three drip infusions per week of 4 hours per infusion with the 1st to 3rd infusion on the 1st, 3rd and 5th day in the first week, with the 4th to 6th infusion on the 8th, 10th and 12th day in the second week and finally with the 7th to 9th infusion on the 15th, 17th and 19th day in the 3rd week.
- the attached diagram shows, at the beginning of the second week until the end of the treatment in the third week, a sudden increase in the platelet count after the 5th day of treatment and then a continuous increase in the platelet count from the 8th to the subsequent 19th day of treatment and a further slowing increase the platelet count at the first check - up on the 29th day and at a later day of discharge FU1 Patients without further addition of the active ingredient according to the invention, wherein the last measured Thrombozypteniere, as already said, about 32.5. 10 9 was.
- the invention is not limited to the use of human recombinant H1.3. Because of the close relationship of the H 1 subtypes, it is obvious for a person skilled in the art to use other human recombinant H 1 subtypes as the active substance as the basis for the active ingredient according to the invention.
- the active ingredient according to the invention preferably consists of the complete, unabridged subtypes of histone proteins.
- the active ingredient according to the invention preferably consists of the complete, unabridged subtypes of histone proteins.
- Such therapeutically effective histone segments are therefore within the range of equivalence of the teaching disclosed herein.
- the therapeutic teaching event of an imminent or present in the initial state of primary disease that can have according to experience thrombocytopenia result, prophylactically and then to use the active ingredient of the invention against a threat of thrombocytopenia when other than in the leukemia, the active ingredient according to the invention against the primary disease is not effective.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES06742792.2T ES2461564T3 (es) | 2005-05-10 | 2006-05-04 | Uso de histonas para fines terapéuticos |
KR1020137019312A KR20130099207A (ko) | 2005-05-10 | 2006-05-04 | 치료 목적을 위한 히스톤의 용도 |
KR1020147031207A KR20140137462A (ko) | 2005-05-10 | 2006-05-04 | 치료 목적을 위한 히스톤의 용도 |
PL06742792T PL1879609T3 (pl) | 2005-05-10 | 2006-05-04 | Zastosowanie histonu w celach terapeutycznych |
CA2608019A CA2608019C (en) | 2005-05-10 | 2006-05-04 | Use of histones to treat thrombocytopenia |
JP2008510461A JP2008540473A (ja) | 2005-05-10 | 2006-05-04 | 治療のためのヒストンの使用方法 |
US11/920,050 US20090305966A1 (en) | 2005-05-10 | 2006-05-04 | Use of histones for therapeutic purposes |
EP06742792.2A EP1879609B1 (de) | 2005-05-10 | 2006-05-04 | Verwendung von histonen zu therapeutischen zwecken |
US13/758,950 US8962562B2 (en) | 2005-05-10 | 2013-02-04 | Use of histones for therapeutic purposes |
US14/588,836 US20150119331A1 (en) | 2005-05-10 | 2015-01-02 | Use of Histones for Therapeutic Purposes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005022319.2 | 2005-05-10 | ||
DE102005022319A DE102005022319A1 (de) | 2005-05-10 | 2005-05-10 | Verwendung von Histonen zu therapeutischen Zwecken |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/920,050 A-371-Of-International US20090305966A1 (en) | 2005-05-10 | 2006-05-04 | Use of histones for therapeutic purposes |
US13/758,950 Continuation US8962562B2 (en) | 2005-05-10 | 2013-02-04 | Use of histones for therapeutic purposes |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006119912A2 true WO2006119912A2 (de) | 2006-11-16 |
WO2006119912A3 WO2006119912A3 (de) | 2007-04-12 |
Family
ID=37310925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/004167 WO2006119912A2 (de) | 2005-05-10 | 2006-05-04 | Verwendung von histonen zu therapeutischen zwecken |
Country Status (12)
Country | Link |
---|---|
US (3) | US20090305966A1 (de) |
EP (1) | EP1879609B1 (de) |
JP (2) | JP2008540473A (de) |
KR (3) | KR20140137462A (de) |
CN (1) | CN101171027A (de) |
CA (2) | CA2811995A1 (de) |
DE (1) | DE102005022319A1 (de) |
ES (1) | ES2461564T3 (de) |
HU (1) | HUE027070T2 (de) |
PL (1) | PL1879609T3 (de) |
PT (1) | PT1879609E (de) |
WO (1) | WO2006119912A2 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005022319A1 (de) * | 2005-05-10 | 2006-11-23 | Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh | Verwendung von Histonen zu therapeutischen Zwecken |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0973541A1 (de) | 1997-04-11 | 2000-01-26 | SYMBIOTEC Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie GmbH | Krebstherapeutikum/prophylaktikum und diagnose zur charakterisierung von krebszellen mit individueller eigenschaft |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH075476B2 (ja) * | 1984-01-12 | 1995-01-25 | ルッシュ、フォルケル | ホルモン活性を有する生物学的作用物質、その製法およびヒストンの医薬的用途 |
JPH03502582A (ja) * | 1988-05-31 | 1991-06-13 | シェリング・バイオテック・コーポレーション | 骨髄性白血病の治療方法 |
DE4000154A1 (de) * | 1990-01-04 | 1991-07-11 | Symbiotec Gmbh | Chemotherapeutisches mittel, insbesondere zur behandlung von krebserkrankungen |
US5571686A (en) * | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
US20030017987A1 (en) * | 1997-04-11 | 2003-01-23 | Michael Zeppezauer | Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties |
US6884423B1 (en) * | 1998-08-13 | 2005-04-26 | Symbiotec Gmbh | Antimicrobial histone H1 compositions, kits, and methods of use thereof |
AU4676500A (en) * | 1999-04-28 | 2000-11-10 | Northwestern University | Localization of major peptide autoepitopes for nucleosome specific t cells of systemic lupus erythematosus |
DE10001113A1 (de) * | 2000-01-13 | 2001-07-26 | Strathmann Ag & Co | Rekombinante Herstellung von humanen Histon 1-Subtypen sowie deren Verwendung für therapeutische Zwecke |
JP3986439B2 (ja) | 2001-02-07 | 2007-10-03 | 中外製薬株式会社 | 造血器腫瘍の治療剤 |
WO2002067907A1 (en) | 2001-02-22 | 2002-09-06 | Philadelphia, Health And Education Corporation | Compositions and methods for preventing platelet aggregation |
JP2002355048A (ja) * | 2001-05-31 | 2002-12-10 | Communication Research Laboratory | リボヌクレオチド還元酵素r1とその阻害ペプチド |
DE10230223A1 (de) * | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
WO2004039336A2 (en) * | 2002-10-31 | 2004-05-13 | Oregon Health & Science University | Use of thiol-based compositions in treating chemotherapeutic agent-induced thrombocytopenia |
DE102005022319A1 (de) * | 2005-05-10 | 2006-11-23 | Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der Biotechnologie Mbh | Verwendung von Histonen zu therapeutischen Zwecken |
-
2005
- 2005-05-10 DE DE102005022319A patent/DE102005022319A1/de not_active Ceased
-
2006
- 2006-05-04 PT PT67427922T patent/PT1879609E/pt unknown
- 2006-05-04 ES ES06742792.2T patent/ES2461564T3/es active Active
- 2006-05-04 EP EP06742792.2A patent/EP1879609B1/de not_active Not-in-force
- 2006-05-04 US US11/920,050 patent/US20090305966A1/en not_active Abandoned
- 2006-05-04 JP JP2008510461A patent/JP2008540473A/ja active Pending
- 2006-05-04 HU HUE06742792A patent/HUE027070T2/en unknown
- 2006-05-04 CA CA2811995A patent/CA2811995A1/en not_active Abandoned
- 2006-05-04 WO PCT/EP2006/004167 patent/WO2006119912A2/de active Application Filing
- 2006-05-04 PL PL06742792T patent/PL1879609T3/pl unknown
- 2006-05-04 KR KR1020147031207A patent/KR20140137462A/ko active Search and Examination
- 2006-05-04 KR KR1020077025805A patent/KR20080007351A/ko not_active Application Discontinuation
- 2006-05-04 CA CA2608019A patent/CA2608019C/en not_active Expired - Fee Related
- 2006-05-04 CN CNA2006800157213A patent/CN101171027A/zh active Pending
- 2006-05-04 KR KR1020137019312A patent/KR20130099207A/ko active Application Filing
-
2013
- 2013-02-04 US US13/758,950 patent/US8962562B2/en not_active Expired - Fee Related
- 2013-05-15 JP JP2013102973A patent/JP5667238B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-02 US US14/588,836 patent/US20150119331A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0973541A1 (de) | 1997-04-11 | 2000-01-26 | SYMBIOTEC Gesellschaft zur Forschung und Entwicklung auf dem Gebiet der Biotechnologie GmbH | Krebstherapeutikum/prophylaktikum und diagnose zur charakterisierung von krebszellen mit individueller eigenschaft |
Non-Patent Citations (2)
Title |
---|
ARTIKEL VON REINER CLASS ET AL., AM. J. CLIN. ONCOL., vol. 19, no. 5, 1996 |
ARTIKEL VON SEMINA O.V. ET AL., RADIATSIONNAIA BIOLOGIIA, RADIOECOLOGIIA, vol. 34, no. 4-5, July 1994 (1994-07-01) |
Also Published As
Publication number | Publication date |
---|---|
JP5667238B2 (ja) | 2015-02-12 |
US8962562B2 (en) | 2015-02-24 |
KR20080007351A (ko) | 2008-01-18 |
CA2811995A1 (en) | 2006-11-16 |
US20150119331A1 (en) | 2015-04-30 |
CN101171027A (zh) | 2008-04-30 |
EP1879609B1 (de) | 2014-03-12 |
CA2608019C (en) | 2013-07-02 |
KR20140137462A (ko) | 2014-12-02 |
US20090305966A1 (en) | 2009-12-10 |
JP2008540473A (ja) | 2008-11-20 |
DE102005022319A1 (de) | 2006-11-23 |
HUE027070T2 (en) | 2016-08-29 |
US20140148391A1 (en) | 2014-05-29 |
JP2013151573A (ja) | 2013-08-08 |
WO2006119912A3 (de) | 2007-04-12 |
EP1879609A2 (de) | 2008-01-23 |
PT1879609E (pt) | 2014-06-09 |
CA2608019A1 (en) | 2006-11-16 |
PL1879609T3 (pl) | 2014-08-29 |
ES2461564T3 (es) | 2014-05-20 |
KR20130099207A (ko) | 2013-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1037648B1 (de) | Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen | |
DE4214953C2 (de) | Arzneimittel zur Erhöhung des Testosteronspiegels | |
DE19644998C1 (de) | Verwendung von Adamantanaminen oder strukturanaloger Verbindungen zur Bekämpfung von Borna Disease Virus und zur Prophylaxe und Behandlung von Affekterkrankungen und anderen mit BDV-Infektionen verbundenen Störungen bei Mensch und Tier | |
DE4311870C2 (de) | Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen | |
EP1879609B1 (de) | Verwendung von histonen zu therapeutischen zwecken | |
DE19726871C1 (de) | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe | |
Keyßer | Safety aspects of the treatment with glucocorticoids for rheumatoid arthritis | |
Engel et al. | Der Tagesgang der Phasenkoppelung zwischen Herzschlag und Atmung in Ruhe und seine Beeinflussung durch dosierte Arbeitsbelastung | |
Boros et al. | Die klinische Bedeutung der Tachykardie | |
EP0597071B1 (de) | Androgene zur stimulierung des zentralnervensystems | |
DE2057174A1 (de) | Pharmazeutisches Produkt,insbesondere injizierbares Lokalanaesthetikum | |
DE4103451C2 (de) | Verwendungen des Wirkstoffes Sulpirid in seiner R- bzw. S-Form | |
Bischoff et al. | Spannungskopfschmerz | |
Isler et al. | Farbstoff-Verdünnungskurven bei Herzklappenfehlern | |
DE2220500C3 (de) | Analgetikum | |
Riemann et al. | Schlaf, Depression und insomnische Beschwerden | |
Schuster et al. | Intravenös verabreichte Immunglobuline bei Asthma bronchiale: eine therapeutische Alternative? | |
Brunner | Ueber abszedierende Brucella abortus Bang-Strumitis. | |
WO1987002248A1 (en) | Analgesic and anti-inflammatory medicine made from plants | |
EP0291751A2 (de) | Pharmazeutisches Kombinationspräparat | |
DE3513391A1 (de) | Neues nootropikum | |
Greppi | Die Ernährung des alternden Menschen | |
DE10237146A1 (de) | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose | |
Jerusalem et al. | Elektronenmikroskopische myopathologische Biopsiebefunde bei Hypercorticismus durch ein ACTH-aktives Lebercarcinom | |
HoF et al. | Tracheabronchiale Clearance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2006742792 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1858/MUMNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077025805 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680015721.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2608019 Country of ref document: CA Ref document number: 2008510461 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006742792 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11920050 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020137019312 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020147031207 Country of ref document: KR |